Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Small molecules inhibit ex vivo tumor growth in bone.

Zhou D, Bum-Erdene K, Xu D, Liu D, Tompkins D, Sulaiman RS, Corson TW, Chirgwin JM, Meroueh SO.

Bioorg Med Chem. 2018 Dec 15;26(23-24):6128-6134. doi: 10.1016/j.bmc.2018.11.025. Epub 2018 Nov 16.

PMID:
30470597
2.

The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.

Lontos K, Adamik J, Tsagianni A, Galson DL, Chirgwin JM, Suvannasankha A.

Front Endocrinol (Lausanne). 2018 Jun 19;9:322. doi: 10.3389/fendo.2018.00322. eCollection 2018. Review.

3.

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.

Juárez P, Fournier PGJ, Mohammad KS, McKenna RC, Davis HW, Peng XH, Niewolna M, Mauviel A, Chirgwin JM, Guise TA.

Oncotarget. 2017 Sep 23;8(49):86447-86462. doi: 10.18632/oncotarget.21200. eCollection 2017 Oct 17.

4.

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T.

Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1.

5.

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.

6.

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.

Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM.

Oncotarget. 2015 Aug 14;6(23):19647-60.

7.

Role of bone-anabolic agents in the treatment of breast cancer bone metastases.

Suvannasankha A, Chirgwin JM.

Breast Cancer Res. 2014;16(6):484. Review.

8.

Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.

Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM.

Breast Cancer Res. 2014 Dec 2;16(6):458. doi: 10.1186/s13058-014-0458-y.

9.

Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA.

Cancer Res. 2012 Dec 1;72(23):6247-56. doi: 10.1158/0008-5472.CAN-12-1444. Epub 2012 Sep 20.

10.

The stem cell niche as a pharmaceutical target for prevention of skeletal metastases.

Chirgwin JM.

Anticancer Agents Med Chem. 2012 Mar;12(3):187-93. Review.

PMID:
22044002
11.

Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor.

Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, Guise TA.

J Bone Miner Res. 2011 Oct;26(10):2523-36. doi: 10.1002/jbmr.450.

12.

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.

Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA.

PLoS One. 2009 Sep 3;4(9):e6896. doi: 10.1371/journal.pone.0006896.

13.

Agents targeting prostate cancer bone metastasis.

Mohammad KS, Fournier PG, Guise TA, Chirgwin JM.

Anticancer Agents Med Chem. 2009 Dec;9(10):1079-88. Review.

PMID:
19719455
14.

Assessing new bone formation in neonatal calvarial organ cultures.

Mohammad KS, Chirgwin JM, Guise TA.

Methods Mol Biol. 2008;455:37-50. doi: 10.1007/978-1-59745-104-8_3.

PMID:
18463809
15.

Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function.

Sackett DL, Ozbun L, Zudaire E, Wessner L, Chirgwin JM, Cuttitta F, Martínez A.

Endocrinology. 2008 Jun;149(6):2888-98. doi: 10.1210/en.2007-1763. Epub 2008 Mar 6.

16.

Molecular biology of bone metastasis.

Kingsley LA, Fournier PG, Chirgwin JM, Guise TA.

Mol Cancer Ther. 2007 Oct;6(10):2609-17. Review.

17.

Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.

Chirgwin JM, Guise TA.

J Cell Biochem. 2007 Dec 15;102(6):1333-42. Review.

PMID:
17907152
18.

Breaking new ground to build bone.

Kingsley LA, Chirgwin JM, Guise TA.

Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10753-4. Epub 2007 Jun 20. Review. No abstract available.

19.

Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases.

Siclari VA, Guise TA, Chirgwin JM.

Cancer Metastasis Rev. 2006 Dec;25(4):621-33. Review.

PMID:
17165131
20.

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA.

Mol Endocrinol. 2007 Feb;21(2):486-98. Epub 2006 Oct 26.

21.

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.

Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s. Review.

22.

New insights into the role of T cells in the vicious cycle of bone metastases.

Fournier PG, Chirgwin JM, Guise TA.

Curr Opin Rheumatol. 2006 Jul;18(4):396-404. Review.

PMID:
16763461
23.

The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells.

Bartholin L, Wessner LL, Chirgwin JM, Guise TA.

Cancer Lett. 2007 Feb 8;246(1-2):230-6. Epub 2006 Apr 17.

PMID:
16616811
24.

Does prostate-specific antigen contribute to bone metastases?

Chirgwin JM, Guise TA.

Clin Cancer Res. 2006 Mar 1;12(5):1395-7. Review. No abstract available.

25.

Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis.

Zudaire E, Martínez A, Garayoa M, Pío R, Kaur G, Woolhiser MR, Metcalfe DD, Hook WA, Siraganian RP, Guise TA, Chirgwin JM, Cuttitta F.

Am J Pathol. 2006 Jan;168(1):280-91.

26.

Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ.

Cancer Res. 2005 Dec 1;65(23):11001-9.

27.

Molecular mechanisms of breast cancer metastases to bone.

Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM.

Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53. Review.

PMID:
15807924
28.

Interactions between tumor and bone alter the phenotypes of both.

Chirgwin JM, Guise TA.

J Musculoskelet Neuronal Interact. 2003 Dec;3(4):278-81; discussion 292-4. No abstract available.

29.

Tumor-bone cellular interactions in skeletal metastases.

Chirgwin JM, Mohammad KS, Guise TA.

J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18. Review.

30.

Transforming growth factor-beta in osteolytic breast cancer bone metastases.

Guise TA, Chirgwin JM.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S32-8. Review.

PMID:
14600590
31.

Role of bisphosphonates in prostate cancer bone metastases.

Guise TA, Chirgwin JM.

Semin Oncol. 2003 Oct;30(5):717-23. Review.

PMID:
14571419
32.

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Yin JJ, Mohammad KS, Käkönen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA.

Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9. Epub 2003 Aug 26.

33.

Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.

Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA.

J Biol Chem. 2002 Jul 5;277(27):24571-8. Epub 2002 Apr 18.

34.

Molecular mechanisms of tumor-bone interactions in osteolytic metastases.

Chirgwin JM, Guise TA.

Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Review.

PMID:
11186331
35.

Reproductive tissue renin gene expression in preeclampsia.

Shah DM, Banu JM, Chirgwin JM, Tekmal RR.

Hypertens Pregnancy. 2000;19(3):341-51.

PMID:
11118408
36.

Fusions to maltose-binding protein: control of folding and solubility in protein purification.

Sachdev D, Chirgwin JM.

Methods Enzymol. 2000;326:312-21. No abstract available.

PMID:
11036650
37.

Rabbit phosphoglucose isomerase/neuroleukin/autocrine motility factor: cloning via interspecies identity.

Li X, Chirgwin JM.

Biochim Biophys Acta. 2000 Feb 9;1476(2):363-7.

PMID:
10669800
38.
39.
40.

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA.

J Clin Invest. 1999 Jan;103(2):197-206.

41.

Truncations at the NH2 terminus of rhodanese destabilize the enzyme and decrease its heterologous expression.

Trevino RJ, Tsalkova T, Kramer G, Hardesty B, Chirgwin JM, Horowitz PM.

J Biol Chem. 1998 Oct 23;273(43):27841-7.

42.

Epitope mapping of recombinant human procathepsin D.

Sachdev D, Ohsaki Y, Roodman GD, Chirgwin JM.

Adv Exp Med Biol. 1998;436:185-9. No abstract available.

PMID:
9561217
43.

Expression of chimeric human aspartic proteinases.

Chirgwin JM, Schultz S, Sachdev D.

Adv Exp Med Biol. 1998;436:139-46. No abstract available.

PMID:
9561211
44.

Purification, amino acid sequence, and cDNA sequence of a novel calcium-precipitating proteolipid involved in calcification of corynebacterium matruchotii.

van Dijk S, Dean DD, Liu Y, Zhao Y, Chirgwin JM, Schwartz Z, Boyan BD.

Calcif Tissue Int. 1998 Apr;62(4):350-8.

PMID:
9504961
45.

Order of fusions between bacterial and mammalian proteins can determine solubility in Escherichia coli.

Sachdev D, Chirgwin JM.

Biochem Biophys Res Commun. 1998 Mar 27;244(3):933-7.

PMID:
9535771
46.
47.

Preformed GroES oligomers are not required as functional cochaperonins.

Seale JW, Chirgwin JM, Demeler B, Horowitz PM.

J Protein Chem. 1997 Oct;16(7):661-8.

PMID:
9330224
48.

Chinese hamster rhodanese cDNA: activity of the expressed protein is not blocked by a C-terminal extension.

Trevino RJ, Hunt J, Horowitz PM, Chirgwin JM.

Protein Expr Purif. 1995 Oct;6(5):693-9.

PMID:
8535164
49.

Lysine residues in the C-terminal lobe and lysosomal targeting of procathepsin D.

Schorey JS, Fortenberry SC, Chirgwin JM.

J Cell Sci. 1995 May;108 ( Pt 5):2007-15.

50.

Role of glycosylation in the expression of human procathepsin D.

Fortenberry SC, Schorey JS, Chirgwin JM.

J Cell Sci. 1995 May;108 ( Pt 5):2001-6.

Supplemental Content

Loading ...
Support Center